These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Some statistical issues in the design of HIV-1 vaccine and treatment trials. Gilbert PB Stat Methods Med Res; 2000 Jun; 9(3):207-29. PubMed ID: 11084705 [TBL] [Abstract][Full Text] [Related]
23. Influenza vaccine efficacy trials: a simulation approach to understand failures from the past. Benoit A; Legrand C; Dewé W Pharm Stat; 2015; 14(4):294-301. PubMed ID: 25924929 [TBL] [Abstract][Full Text] [Related]
25. Beyond efficacy: The full public health impact of vaccines. Saadatian-Elahi M; Horstick O; Breiman RF; Gessner BD; Gubler DJ; Louis J; Parashar UD; Tapia R; Picot V; Zinsou JA; Nelson CB Vaccine; 2016 Feb; 34(9):1139-47. PubMed ID: 26808648 [TBL] [Abstract][Full Text] [Related]
26. Handling missing data in vaccine clinical trials for immunogenicity and safety evaluation. Li X; Wang WW; Liu GF; Chan IS J Biopharm Stat; 2011 Mar; 21(2):294-310. PubMed ID: 21391003 [TBL] [Abstract][Full Text] [Related]
27. Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward. Guy B; Briand O; Lang J; Saville M; Jackson N Vaccine; 2015 Dec; 33(50):7100-11. PubMed ID: 26475445 [TBL] [Abstract][Full Text] [Related]
28. An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure. Taylor DJ; Grobler A; Abdool Karim SS Clin Trials; 2012 Aug; 9(4):377-84. PubMed ID: 22610168 [TBL] [Abstract][Full Text] [Related]
30. [From the licensure of vaccines to the recommendation of the Standing Committee on Vaccination in Germany : criteria for the assessment of benefits and risks]. Pfleiderer M; Wichmann O Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Mar; 58(3):263-73. PubMed ID: 25566841 [TBL] [Abstract][Full Text] [Related]
31. Use of placebos in Phase 1 preventive HIV vaccine clinical trials. Huang Y; Karuna ST; Janes H; Frahm N; Nason M; Edlefsen PT; Kublin JG; Corey L; McElrath MJ; Gilbert PB Vaccine; 2015 Feb; 33(6):749-52. PubMed ID: 25454855 [TBL] [Abstract][Full Text] [Related]
32. Improving immunogenicity, efficacy and safety of vaccines through innovation in clinical assay development and trial design: the Phacilitate Vaccine Forum, Washington D.C. 2011. Moldovan IR; Tary-Lehmann M Hum Vaccin; 2011 Jun; 7(6):610-2. PubMed ID: 21602620 [TBL] [Abstract][Full Text] [Related]
33. A clinical development paradigm for cancer vaccines and related biologics. Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G; J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079 [TBL] [Abstract][Full Text] [Related]
35. Safety considerations for new vaccine development. Ellenberg SS Pharmacoepidemiol Drug Saf; 2001; 10(5):411-5. PubMed ID: 11802587 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of vaccine safety after the events of 11 September 2001: role of cohort and case-control studies. Chen RT Vaccine; 2004 May; 22(15-16):2047-53. PubMed ID: 15121321 [TBL] [Abstract][Full Text] [Related]
37. Parent perspectives on consent for the linkage of data to evaluate vaccine safety: a randomised trial of opt-in and opt-out consent. Berry JG; Ryan P; Duszynski KM; Braunack-Mayer AJ; Carlson J; Xafis V; Gold MS; Clin Trials; 2013; 10(3):483-94. PubMed ID: 23568940 [TBL] [Abstract][Full Text] [Related]
38. Evaluating the safety of new vaccines: summary of a workshop. Ellenberg SS; Foulkes MA; Midthun K; Goldenthal KL Am J Public Health; 2005 May; 95(5):800-7. PubMed ID: 15855455 [TBL] [Abstract][Full Text] [Related]